Skip to content

Evaluating the Accuracy and Practical Utility of AI-Enhanced 12-Lead ECG

Toho Multicenter Registry for Evaluating the Accuracy and Practical Utility of AI-Enhanced 12-Lead ECG in Monitoring Atrial Fibrillation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07316231
Enrollment
350
Registered
2026-01-05
Start date
2025-09-11
Completion date
2028-08-31
Last updated
2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AI-enhanced 12-lead ECG

Brief summary

Atrial fibrillation (AF) is a major cause of heart failure and ischemic stroke, making early detection and intervention critically important. However, timely ECG recording during paroxysmal episodes is often difficult, leading to delayed diagnosis. Recently, an AI-enhanced 12-lead ECG equipped with a hidden AF risk estimation function has been introduced. This technology analyzes sinus rhythm ECGs and stratifies the likelihood of prior AF into four risk categories. Although this novel approach may facilitate earlier AF detection and optimize the timing of therapeutic intervention, its clinical accuracy and real-world utility remain insufficiently validated. Therefore, this multicenter study aims to evaluate the diagnostic performance and clinical usefulness of AI-based AF risk assessment and to clarify its association with subsequent AF incidence and patient outcomes.

Interventions

None listed

Sponsors

Toho University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥18 years 2. Patients with atrial fibrillation or atrial tachycardia (AF/AT) in whom sinus rhythm is maintained or can be confirmed at the time of ECG recording

Exclusion criteria

1. Age \<18 years 2. History of long-standing persistent or permanent atrial fibrillation 3. Frequent premature beats preventing acquisition of a sinus rhythm ECG 4. Patients with no clinical indication to suspect atrial fibrillation

Design outcomes

Primary

MeasureTime frame
the 1-2-year composite endpoint of all-cause death and major adverse cardiac events (MACE), including AF recurrenceone-two year

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026